Mercado global de vacinas contra a febre tifóide – Tendências do setor e previsão para 2029

Análise e dimensão do mercado                              

De acordo com um estudo publicado na Lancet: Infectious Diseases, a febre tifóide infeta 21,6 milhões de pessoas em todo o mundo e mata cerca de 200.000 pessoas por ano. Além disso, a instabilidade económica na América Latina e noutras economias em desenvolvimento resultou num saneamento deficiente e no acesso restrito a água potável e alimentos, colocando as pessoas em risco de contrair febre tifóide. A Salmonella typhi produz febre tifóide, que provoca sintomas como temperatura elevada, dor de cabeça, perda de apetite, prisão de ventre e náuseas. A febre tifóide propaga-se principalmente em áreas com saneamento deficiente e água contaminada. As vacinas contra a febre tifóide são formulações biológicas que conferem imunidade e proteção contra a febre tifóide nos seres humanos.

A Data Bridge Market Research analisa que o mercado das vacinas contra a febre tifóide foi avaliado em 321,48 milhões de dólares em 2021 e deverá atingir os 719,77 milhões de dólares até 2029, registando um CAGR de 10,6% durante o período de previsão de 2022 a 2029. Além dos insights de mercado como o valor de mercado, taxa de crescimento, segmentos de mercado, cobertura geográfica, participantes do mercado e cenário de mercado, o relatório de mercado com curadoria da equipa de pesquisa de mercado da Data Bridge inclui também análise especializada aprofundada, epidemiologia do doente, análise de pipeline, análise de preços e quadro regulamentar.

Âmbito do relatório e segmentação de mercado

Market Definition

Typhoid fever, commonly known as Salmonella typhi or Salmonella enterica serotype Typhi, is a bacterial infection caused by Salmonella typhi. Typhoid fever is most commonly caused by consuming contaminated food or water. Typhoid immunizations help to prevent and protect against typhoid fever. The World Health Organization (WHO) has advised using three types of typhoid vaccines: live attenuated vaccine, capsular polysaccharide vaccines, and conjugate vaccines.

Typhoid Vaccine Market Dynamics

Drivers

• Rise in the prevalence of typhoid

The surging prevalence of typhoid in various emerging economies is a major factor driving the typhoid vaccine market's growth rate during the forecast period of 2022 to 2029. According to estimates from the International Health Metrics and Evaluation (IHME), over 12 million cases of typhoid fever were reported worldwide in 2016, resulting in around 130,000 deaths. The risk of typhoid is increased among people who do not have access to clean water and sanitation. Poor communities and vulnerable people, such as children, are particularly vulnerable.

• Increasing investment for healthcare infrastructure

Another significant factor influencing the growth rate of typhoid vaccine market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aims to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.

Furthermore, rising initiatives by public and private organizations to spread awareness will expand the typhoid vaccine market. Additionally, the sedentary lifestyle of people and surging geriatric population will result in the expansion of the typhoid vaccine market. Along with this, the presence of immunization campaigns across the globe and favourable reimbursement policies will enhance the market's growth rate.

Opportunities

• Rising number of government initiatives for the development of innovative products

The rising number of government initiatives to develop innovative products is expected to provide beneficial market opportunities. World Health Organization (WHO), Gavi, Bill and Melinda Gates Foundation, and others are all working hard to raise awareness about typhoid and drive immunization efforts against the disease. In December 2017, the World Health Organization (WHO) pre-qualified Typbar TCV, a typhoid conjugate vaccine (TCV) manufactured by Bharat Biotech. The vaccine can now be purchased and delivered to nations funded by UNICEF, the Pan-American Health Organization (PAHO), and the GAVI (Vaccine Alliance). Various companies' regular initiatives are projected to assist market expansion during the forecast period.

Moreover, rising investment for the development of advanced technologies and increase in the number of emerging markets will further provide beneficial opportunities for the typhoid vaccine market growth during the forecast period.

Restraints/Challenges

On the other hand, the high cost associated with vaccine and its development will obstruct the market's growth rate. Developing economies' lack of healthcare infrastructure and the dearth of skilled professionals will challenge the typhoid vaccine market. Additionally, side effects of vaccine such as pain and mild fever will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.

This typhoid vaccine market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the typhoid vaccine market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

The World Health Organization estimates that 11-20 million cases of typhoid fever occur globally each year, resulting in 128 000–161 000 fatalities.

Typhoid vaccine market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Typhoid Vaccine Market

The COVID-19 outbreak has emerged as the world's most serious threat. This problem will be alarming, particularly in developing nations around the world, because it will result in reduced imports owing to global trade disruptions, which will exacerbate shortages of medical supplies and other items, resulting in significant price rises. The World Health Organization and UNICEF have expressed concern over a global fall in youngsters receiving life-saving immunizations. This is due to the COVID-19 pandemic disrupting the delivery and acceptance of vaccine programs. In 2019, UNICEF bought an estimated 2.43 billion vaccination doses for over 100 countries, reaching around 45 percent of the world's children under the age of five. However, companies frequently use product launches and expansion strategies to expand their global footprint and meet rising demand. Market participants frequently use these tactics to enhance their product portfolio.

Recent Development

• In April 2022, The Government of Nepal had announced the launch of a new vaccine campaign called Typhoid Conjugate Vaccine (TCV) into the routine immunization programme across the country. It is in collaboration with Gavi, the Vaccine Alliance, UNICEF, WHO, and other partners. The goal of the program was to obtain 95% coverage of roughly 7.5 million children with the typhoid conjugate vaccine (TCV) while also identifying "zero-dose" children and those who have missed other routine immunizations.

Global Typhoid Vaccine Market Scope

The typhoid vaccine market is segmented on the basis of type, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Live Attenuated Vaccine
• Monovalent Typhoid Vaccines
• Capsular Polysaccharide Vaccines
• Conjugate Vaccine
• Others

Route of Administration

• Oral
• Parenteral

End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Typhoid Vaccine Market Regional Analysis/Insights

The typhoid vaccine market is analysed and market size insights and trends are provided by country, type, route of administration, end-users and distribution channel as referenced above.

The countries covered in the typhoid vaccine market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

A América do Norte domina o mercado das vacinas contra a febre tifóide em termos de quota de mercado e receitas de mercado e continuará a florescer o seu domínio durante o período de previsão. Isto deve-se à presença de grandes intervenientes-chave e o aumento dos gastos em saúde impulsionará ainda mais a taxa de crescimento do mercado nesta região. Além disso, o aumento da sensibilização dos doentes e a elevada procura de vacinas impulsionarão ainda mais a taxa de crescimento do mercado nesta região.

Espera-se que a Ásia-Pacífico cresça durante o período de previsão de 2022-2029 devido ao aumento da prevalência de doenças tifóides e às diretrizes regulamentares favoráveis ​​nesta região. Além disso, o desenvolvimento de infra-estruturas de saúde e o aumento das iniciativas governamentais para programas de imunização impulsionarão ainda mais a taxa de crescimento do mercado nesta região.

A secção do país do relatório também fornece fatores individuais de impacto no mercado e alterações na regulamentação do mercado interno que impactam as tendências atuais e futuras do mercado. Pontos de dados como a análise da cadeia de valor a jusante e a montante, tendências técnicas e análise das cinco forças de Porter, estudos de caso são alguns dos indicadores utilizados para prever o cenário de mercado para países individuais. Além disso, são considerados a presença e disponibilidade de marcas globais e os desafios enfrentados devido à grande ou escassa concorrência de marcas locais e nacionais, o impacto das tarifas nacionais e das rotas comerciais, ao mesmo tempo que se fornece uma análise de previsão dos dados do país.   

Análise do cenário competitivo e da quota de mercado da vacina contra a febre tifóide

O panorama competitivo do mercado de vacinas contra a febre tifóide fornece detalhes por concorrente. Os detalhes incluídos são a visão geral da empresa, finanças da empresa, receitas geradas, potencial de mercado, investimento em investigação e desenvolvimento, novas iniciativas de mercado, presença global, localizações e instalações de produção, capacidades de produção, pontos fortes e fracos da empresa , lançamento de produto, largura e amplitude do produto, aplicação domínio. Os dados acima fornecidos estão apenas relacionados com o foco das empresas relacionado com o mercado das vacinas contra a febre tifóide.

Alguns dos principais players que operam no mercado das vacinas contra a febre tifóide são:

• (EUA)
• GlaxoSmithKline plc (Reino Unido)
• Novartis AG (Suíça)
• Mylan NV (EUA)
• Teva Pharmaceutical Industries Ltd.(Israel)
• Sanofi (França)
• AstraZeneca (Reino Unido)
• Johnson & Johnson Private Limited (EUA)
• Merck & Co., Inc.
• F. Hoffmann-La Roche Ltd. (Suíça)
• bioMérieux SA (França)
• Amgen Inc.
• Takeda Pharmaceutical Company Limited (Japão)
• Sun Pharmaceutical Industries Ltd. (Índia)
• Lupin (Índia)
• Mallinckrodt (EUA)
• EMERGENTE (EUA)
• Bio Farma (Indonésia)
• Bharat Biotech (Índia)
• BIO-MED (Índia)

SKU-53233